Loading…
Artelo Biosciences Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ARTL.
▼ -99.7% over 5Y.
today you would have $2.36▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $32.94 | $171.72 | $226.80 | $468.18 | |
| P/B | 3.8x | — | 11.4x | 3.4x | 3.8x |
| EPS | -$37.56 | -$54.90 | -$56.52 | -$64.08 | |
| ROE | -79.04% | — | -343.93% | -79.04% | -51.97% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GCTKGlucotrack, Inc. | $0.28 | 0.0x | — | — | -620.63% | $225.08K |
| NXLNexalin Technology, Inc. | $0.25 | — | 3.6x | — | -240.25% | $213.88K |
| VTAKCatheter Precision, Inc. | $0.20 | — | 0.0x | — | -111.35% | $724.42K |
| NIVFNewGenIvf Group Ltd | $0.34 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Company description provided by Yahoo Finance.
| 0.0x |
| 0.0x |
| — |
| 79.40% |
| $833.53K |
| BDRXBiodexa Pharmaceuticals Plc | $0.87 | — | 0.0x | — | -64.72% | $893.33K |
| BJDXBluejay Diagnostics, Inc. | $0.90 | — | 0.2x | — | -98.89% | $931.24K |